NORFLUAZEPAM NO FURTHER A MYSTERY

LC–PDA–MS Evaluation of sheet B; PDA chromatogram a, TIC b, and UV spectra of peak two c and of peak 2b d, and ESI mass spectra of peak 2 e and of peak 2b fLC–PDA–MS analysis of sheet B; PDA chromatogram a, TIC b, and UV spectra of peak 2 c and of peak 2b d, and ESI mass spectra of peak 2 e and of peak 2b fIn 1988, the DEA may have unintent